Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis

To compare the efficacy and tolerability of olsalazine sodium with enteric‐coated mesalazine in inducing endoscopic remission in patients with mild to moderate active ulcerative colitis.

[1]  S. Hanauer,et al.  Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. , 1993, The American journal of gastroenterology.

[2]  Courtney Mg,et al.  Randomized Comparison of Olsalazine and Mesalazine in Prevention of Relapses in Ulcerative Colitis , 1993, Journal of Pediatric Gastroenterology and Nutrition.

[3]  H. Allgayer.  Sulfasalazine and 5-ASA compounds. , 1992, Gastroenterology clinics of North America.

[4]  V. Trimble,et al.  Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis , 1992, The Lancet.

[5]  J. Rask-Madsen,et al.  Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. , 1990, Gut.

[6]  W. Kruis,et al.  Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. , 1989, Gut.

[7]  P. Cann,et al.  Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. , 1989, Gut.

[8]  Ami,et al.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. , 1989, BMJ.

[9]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[10]  D. Present,et al.  Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine , 1987 .

[11]  D. Present,et al.  Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. , 1987, Gastroenterology.

[12]  J. Hardy,et al.  Evaluation of an enteric‐coated delayed‐release 5‐aminosalicylic acid tablet in patients with inflammatory bowel disease , 1987, Alimentary pharmacology & therapeutics.

[13]  A. Richens,et al.  Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. , 1987, Gut.

[14]  F. Bochner,et al.  Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition , 1986, Scandinavian journal of gastroenterology. Supplement.

[15]  W. Kraaz,et al.  Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. , 1986, Gastroenterology.

[16]  C. H. Mason,et al.  Olsalazine in active ulcerative colitis. , 1985, British medical journal.

[17]  W C Blackwelder,et al.  "Proving the null hypothesis" in clinical trials. , 1981, Controlled clinical trials.

[18]  S. Hanauer,et al.  Towards an optimal dosage of oral-5-ASA in ulcerative colitis , 1992 .

[19]  C. H. Mason,et al.  Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. , 1988, Gut.

[20]  S. Bourke,et al.  Investigation of aminoglycoside nephrotoxicity in cystic fibrosis patients. , 1988, Scandinavian journal of gastroenterology. Supplement.

[21]  K. Ewe,et al.  Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects. , 1988, Scandinavian journal of gastroenterology. Supplement.

[22]  C. P. Willoughby,et al.  Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis. , 1988, Scandinavian journal of gastroenterology. Supplement.